Focusing on the Neuroendocrine Tumor Target SEZ6
Neuroendocrine neoplasms/tumors (NENs or NETs) are rare tumors that originate from specialized cells called neuroendocrine...
Jan 02, 2024
Butyrophilin (BTN) family: γδ T Cell Receptor Ligands, Immunomodulators and More
Immunotherapy is an essential option for current disease treatment. However, most patients fail to respond...
Dec 27, 2023
Webinar: Transforming Tumor Research: Engineering MHCs as Versatile Reagents
Speaker Dr. Manhee Suh, Co-founder & CTO, KACTUS What's Inside When dealing with solid tumors...
Dec 20, 2023
Empowering Gene Editing Therapy: The Atlas of Gene Editing Enzymes from KACTUS
Overview By leveraging its sophisticated ‘Structure Aided Design and Multiplex Screening (SAMS™)’ platform, along with...
Dec 05, 2023
AccuBase™ Base Editor Enzyme: Globally In Stock Now
Overview AccuBase™ is a new generation base editing tool independently developed by Base Therapeutics with exclusive...
Dec 01, 2023
AET 2023 in the US
We will be showcasing our products and services at the Antibody Engineering & Therapeutics (AET) event...
Nov 29, 2023
The Role of Delta-like Ligand 3 (DLL3) in Targeted Therapy for Cancer
On November 13, 2023, Legend Biotech officially announced that its wholly-owned subsidiary, Legend Biotech Ireland...
Nov 27, 2023